齐拉西酮联合改良电休克治疗精神分裂症患者疗效及对攻击行为、认知功能的影响

Therapeutic effect of ziprasidone combined with modified electroconvulsive therapy on patients with schizophrenia and the impact on aggressive behavior and cognitive function

ES评分 0

DOI
刊名
Journal of International Psychiatry
年,卷(期) 2024, 51(4)
作者
作者单位

四川省南充市身心医院 ;
南充市身心医院 ;

摘要
摘 要 目的:观察齐拉西酮联合改良电休克(modified electroconvulsive therapy,MECT)对精神分裂症疗效、攻击行为和认知功能的影响。方法:选取2021年1月~2022年2月我院收治的100例精神分裂症患者,随机纳为观察组与对照组,各50例,其中对照组给予齐拉西酮治疗,观察组在此基础上联合MECT治疗。比较两组疗效、外显攻击行为量表(modified overt aggression scale,MOAS)、阳性与阴性症状量表(positive and negative symptom scale,PANSS)、蒙特利尔认知量表(Montreal cognitive assessment,MoCA)及简易智能精神量表(mini-mental state examination,MMSE)评分、血清炎症因子及糖脂代谢水平。结果:观察组疗效总有效率为92.00%,高于对照组的76.00%(P<0.05)。治疗4周后,观察组MOAS、PANSS评分、血清超敏C反应蛋白、白介素-6、肿瘤坏死因子-α水平较对照组低(P<0.05);MoCA、MMSE评分较对照组高(P<0.05)。治疗前后两组空腹血糖、甘油三酯、总胆固醇、低密度脂蛋白及高密度脂蛋白水平比较差异均不显著(P>0.05),且治疗期间两组不良反应发生率无明显差异(P>0.05)。结论:齐拉西酮联合MECT治疗精神分裂症疗效肯定,有助于改善患者症状、攻击行为及认知功能,且能缓解炎症反应,对糖脂代谢影响小,安全性高。
Abstract
Abstract Objective: To observe the effects of ziprasidone combined with modified electroconvulsive therapy (modified electroconvulsive therapy, MECT) on therapeutic effect, aggressive behavior, and cognitive function in patients with schizophrenia. Methods: One hundred patients with schizophrenia admitted to the hospital from January 2021 to February 2022 were selected and randomly divided into the observation group and the control group, with 50 cases in each group. The control group was treated with ziprasidone, and the observation group was treated with MECT on this basis. The two groups were compared on the rapeutic effects, Modified Overt Aggression Scale (modified overt aggression scale, MOAS) scores, Positive and Negative Syndrome Scale (positive and negative symptom scale,PANSS) score, Montreal Cognitive Assessment Scale (Montreal cognitive assessment, MoCA) scores, and Mini Mental State Examination Scale (mini-mental state examination, MMSE) scores , serum inflammatory factors, and glucose and lipid metabolism. Results: The total effective rate of the observation group (92.00%) was higher than that of the control group (76.00%) (P<0.05). After 4 weeks of treatment, MOAS score, PANSS score, serum high-sensitivity C-reactive protein, interleukin-6 and tumor necrosis factor-α levels of the observation group were lower than those of the control group (P<0.05). MoCA score and MMSE score were higher than those of the control group (P<0.05). There was no significant difference in the levels of fasting blood glucose, triglycerides, total cholesterol, low-density lipoprotein, and high-density lipoprotein in the two groups before and after treatment (P>0.05). The incidence rates of adverse reactions in the two groups were comparable (P>0.05). Conclusion: Ziprasidone combined with MECT is effective in the treatment of schizophrenia, which helps to improve the patients’ symptoms, aggressive behavior and cognitive function, and relieve inflammatory response, with little influence on glucose and lipid metabolism and high safety.
关键词
关键词 精神分裂症;齐拉西酮;改良电休克;疗效;攻击行为;阳性与阴性症状量表;认知功能
KeyWord
Key words: Schizophrenia; Ziprasidone; Modified electroconvulsive therapy; Therapeutic effect; Aggressive behavior; Positive and Negative Syndrome Scale; Cognitive function
基金项目
页码 1087-1090
  • 参考文献
  • 相关文献
  • 引用本文

张富超*,续慧蕾,梁丽君,陈丽,廖静. 齐拉西酮联合改良电休克治疗精神分裂症患者疗效及对攻击行为、认知功能的影响 [J]. 国际精神病学杂志. 2024; 51; (4). 1087 - 1090.

  • 文献评论

相关学者

相关机构